Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab
نویسندگان
چکیده
منابع مشابه
Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report
INTRODUCTION Differential diagnosis of thrombotic microangiopathies can be difficult. Atypical hemolytic uremic syndrome is a rare, life-threatening disease caused by uncontrolled chronic activation of alternative complement pathway, resulting in microvascular thrombosis, organ ischemia and damage. Prognosis is poor: up to 65 percent of patients require dialysis or have kidney damage of varying...
متن کاملA Case of Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab
Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) characterized by the triad of hemolytic anemia, thrombocytopenia, and acute renal failure. Eculizumab, a monoclonal complement C5 antibody which prevents the induction of the terminal complement cascade, has recently emerged as a therapeutic option for aHUS. We report a case of aHUS successfully treated with ec...
متن کاملAtypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab
BACKGROUND Atypical hemolytic uremic syndrome is a rare disorder which is known to cause acute thrombotic microangiopathy during pregnancy with poor maternal and fetal outcomes. Atypical hemolytic uremic syndrome is caused mostly by dysregulation of alternative complement pathway secondary to genetic mutations. Most of the cases reported have been in the post-partum period. We report a rare cas...
متن کاملEculizumab in atypical hemolytic-uremic syndrome.
n engl j med 369;14 nejm.org october 3, 2013 1377 [CI], 0.57 to 0.83) for the first 21 days, 1.00 (95% CI, 0.57 to 1.76) for 22 to 60 days, and 0.38 (95% CI, 0.18 to 0.82) for 61 to 90 days. We also await results of trials such as POINT and TARDIS for confirmation of these results in non-Chinese populations. We agree with Jeong that there may be important differences according to the patients’ ...
متن کاملEculizumab for atypical hemolytic-uremic syndrome.
n engl j med 360;5 nejm.org january 29, 2009 542 myocardial infarction or coronary death, a 24% decrease in the need for coronary bypass surgery, and a 17% decrease in the rate of fatal or nonfatal stroke.2 The recently reported results of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin (20 mg per day) show th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Korean Journal of Medicine
سال: 2020
ISSN: 1738-9364,2289-0769
DOI: 10.3904/kjm.2020.95.2.124